logo

Alder Biopharmaceuticals Inc (ALDR)



Trade ALDR now with
  Date
  Headline
6/29/2018 8:34:29 AM Alder BioPharma Says New 6-Month Data For Eptinezumab Demonstrating Improvement In Efficacy In PROMISE 2 Phase 3 Trial
6/29/2018 8:32:59 AM Alder Presents One-Year Data For Eptinezumab From PROMISE 1 Phase 3 Showing Long-Term Efficacy In Episodic Migraine
6/7/2018 8:09:27 AM Alder BioPharma Names Robert Azelby President And CEO
4/25/2018 8:40:55 AM Alder BioPharma Announces New Data From Its PROMISE 1 Phase 3 Clinical Trial Evaluating Eptinezumab
4/24/2018 8:36:20 AM Alder BioPharma Presents 12-Month Data Of Eptinezumab In PROMISE 1 Phase 3 Trial In Episodic Migraine Patients
4/23/2018 8:34:15 AM Alder BioPharma Appoints Eric Carter As Interim Chief Medical Officer
4/16/2018 8:33:45 AM Alder BioPharma Appoints Erin Lavelle To Newly Created Role Of COO
3/20/2018 4:06:58 PM Alder BioPharmaceuticals Appoints Paul Cleveland As Interim President And CEO
2/27/2018 8:28:56 AM RBC Capital Markets Is Cutting ALDER BIOPHARMACEUTICALS INC (ALDR) FY19 Estimate To -3.65 From -2.95
2/27/2018 8:28:42 AM RBC Capital Markets Is Lowering ALDER BIOPHARMACEUTICALS INC (ALDR) FY18 Estimate To -3.87 From -3.75
1/29/2018 10:49:54 PM Alder BioPharma Announces Pricing Of $250 Mln Of 2.50% Convertible Senior Notes Due 2025
1/29/2018 7:11:49 AM Alder BioPharma Announces Offering Of $200 Mln Of Convertible Senior Notes Due 2025